|
Hemato-oncology / Original Article
Real-world use of polatuzumab vedotin combined with bendamustine and rituximab for patients with relapsed or refractory large B-cell lymphoma
Changgon Kim, Sang Eun Yoon, Hyun-Young Kim, Duck Cho, Junhun Cho, Won Seog Kim, Seok Jin Kim
Korean J Intern Med. 2026;41(2):296-306. Published online March 1, 2026
Background/Aims: Polatuzumab vedotin combined with bendamustine and rituximab (Pola-BR) is a treatment option for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), particularly as bridging therapy before chimeric antigen receptor (CAR) T-cell infusion. However, real-world data regarding..
|
|
|
Hemato-oncology / Original Article
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Mi Hwa Heo, Hee Kyung Kim, Hansang Lee, Ji-Yeon Kim, Jin-Seok Ahn, Young-Hyuck Im, Yeon Hee Park
Korean J Intern Med. 2019;34(5):1100-1106. Published online March 16, 2018
Background/Aims: We conducted a retrospective analysis of the clinical activity of fulvestrant in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) previously treated with endocrine therapy and/or chemotherapy..
|
|
|
Hemato-oncology / Original Article
Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
Ji Hyun Lee, Sung-Hyun Kim, Sung Yong Oh, Suee Lee, Hojin Lee, Hye Jung Lee, Hyo-Jin Kim
Korean J Intern Med. 2013;28(3):314-321. Published online May 1, 2013
Background/AimsTo determine the efficacy and toxicity of docetaxel as a third-line therapy for patients with relapsed gastric cancer who have undergone modified oxaliplatin-fluorouracil (m-FOLFOX)-4 and modified irinotecan-fluorouracil (m-FOLFIRI) regimens.
|
|
|
Original Article
ESHAP Salvage Therapy for Refractory and Relapsed Non-Hodgkin's Lymphoma: A Single Center Experience
Sang Hyoung Park, Shin Kim, Ok Bae Ko, Ja Eun Koo, Danbi Lee, Yong Pil Jeong, Jooryung Huh, Sung-Bae Kim, Sang We Kim, Jae-Lyun Lee, Cheolwon Suh
Korean J Intern Med. 2006;21(3):159-164. Published online September 30, 2006
BackgroundThe ESHAP chemotherapy regimen, that is, the combination of the etoposide, methylprednisolone, high-dose cytarabine and cisplatin, has been shown to be active against relapsing or refractory non-Hodgkin's lymphoma (NHL) in previous therapeutic trials. We attempted to..
|
|
|
